Borgastatin 10- 40 mg

Each film coated tablet contains:
• For Borgastatin 10 mg Tablets:

Atorvastatin calcium ……… (Equivalent to Atorvastatin 10 mg)

• For Borgastatin 40 mg Tablets:

Atorvastatin calcium ……… (Equivalent to Atorvastatin 40 mg)


Borgastatin (atorvastatin calcium) is a synthetic lipid-lowering agent. It is a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol.


Borgastatin is indicated as an adjunct to lifestyle changes, including diet, for the reduction of elevated total cholesterol (total-C), LDL-C, triglycerides (TG), the Total-C/HDL-C ratio and for increasing HDL-C in hyperlipidemic and dyslipidemic conditions, including:
• Primary hypercholesterolemia (Type IIa).
• Mixed hyperlipidemia (Type IIb), including familial combined hyperlipidemia,
• Dysbetalipoproteinemia (Type III).
• Hypertriglyceridemia (Type IV).


Patients should be placed on a standard cholesterol-lowering diet before receiving
Borgastatin, and should continue on this diet during treatment with Borgastatin.
The recommended starting dose of Borgastatin is 10 once daily.
Patients who require a large reduction in LDL-C may be require increasing the dose at intervals of four weeks with maximum dose of 80 mg once daily.
The dosage of Borgastatin should be individualized according the baseline LDL-C, total-C/HDL-C ratio and/or TG levels to achieve the recommended desired lipid values at the lowest dose needed to achieve LDL-C desired level.


Borgastatin is generally well tolerated, the most frequent adverse events which may occure:

Constipation, Flatulence, dyspepsia, abdominal pain, arthritis, insomnia, dizziness.


Borgastatin Tablets is contraindicated:

– In patients with hypersensitivity to rosuvastatin.
– In patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 x the upper limit of normal (ULN).
– During pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.


Hepatic Effects
Borgastatin is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal.
Borgastatin should be discontinued or the dose reduced if the level of transaminases is greater than 3 times the upper limit of normal.
Muscle Effects
Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with rosuvastatin and with other HMG-CoA reductase inhibitors.

Borgastatin 10 mg Tablets:

Carton box containing (transparent PVC/Alu) blister of 10 tablets.

Borgastatin 40 mg Tablets:

Carton box containing (transparent PVC/Alu) blister of 10 tablets.
– Store at a temperature not exceeding 30 °C, in a dry place.
– Not to be used except under doctor supervision.

RELATED PRODUCTS: (Cardiovascular Products)

Borgavix 75
Betaxolol 10-20
Rosuvastatin 10